Form 4: Assembly Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Director Lisa Johnson-Pratt acquired 2,750 stock options in Assembly Biosciences, Inc. on May 29, 2024.
Summary
- Lisa Johnson-Pratt, a director of Assembly Biosciences, Inc., reported a transaction on May 29, 2024.
- She acquired 2,750 stock options with an exercise price of $15.06.
- These options vest on the earlier of May 29, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
- Following the transaction, Johnson-Pratt directly owns 2,750 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing her to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: Lisa Johnson-Pratt acquired stock options. |
| 05/29/2025 | Earliest vesting date for the stock options, assuming continuous service. |
| 05/30/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.